Animal models of complement-mediated hypersensitivity reactions to liposomes and other lipid-based nanoparticles.
Intravenous injection of some liposomal drugs, diagnostic agents, micelles and other lipid-based nanoparticles can cause acute hypersensitivity reactions (HSRs) in a high percentage (up to 45%) of patients, with hemodynamic, respiratory and cutaneous manifestations. The phenomenon can be explained with activation of the complement (C) system on the surface of lipid particles, leading to anaphylatoxin (C5a and C3a) liberation and subsequent release reactions of mast cells, basophils and possibly other inflammatory cells in blood. These reactions can be reproduced and studied in pigs, dogs and rats, animal models which differ from each other in sensitivity and spectrum of symptoms. In the most sensitive pig model, a few miligrams of liposome (phospholipid) can cause anaphylactoid shock, characterized by pulmonary hypertension, systemic hypotension, decreased cardiac output and major cardiac arrhythmias. Pigs also display cutaneous symptoms, such as flushing and rash. The sensitivity of dogs to hemodynamic changes is close to that of pigs, but unlike pigs, dogs also react to micellar lipids (such as Cremophor EL) and their response includes pronounced blood cell and vegetative neural changes (e.g., leukopenia followed by leukocytosis, thrombocytopenia, fluid excretions). Rats are relatively insensitive inasmuch as hypotension, their most prominent response to liposomes, is induced only by one or two orders of magnitude higher phospholipid doses (based on body weight) compared to the reactogenic dose in pigs and dogs. It is suggested that the porcine and dog models are applicable for measuring and predicting the (pseudo)allergic activity of particulate "nanodrugs".
Szebeni
János
J
Henry M. Jackson Foundation for the Advancement of Military Medicine, Rockville, MD, USA. jszebeni@gmail.com
Alving
Carl R
CR
Rosivall
László
L
Bünger
Rolf
R
Baranyi
Lajos
L
Bedöcs
Péter
P
Tóth
Miklós
M
Barenholz
Yezheckel
Y
D000706:Anaphylatoxins / Q000276:immunology; D000818:Animals; D003167:Complement Activation / Q000187:drug effects* / Q000276:immunology; D004195:Disease Models, Animal; D004285:Dogs; D004342:Drug Hypersensitivity / Q000276:immunology* / Q000473:pathology; D006801:Humans; D008055:Lipids / Q000009:adverse effects* / Q000494:pharmacology; D008081:Liposomes / Q000009:adverse effects* / Q000494:pharmacology; D053758:Nanoparticles / Q000008:administration & dosage / Q000009:adverse effects*; D051381:Rats; D013045:Species Specificity; D013552:Swine
D000706:Anaphylatoxins; D008055:Lipids; D008081:Liposomes